Low Dose Oral Minoxdil in Androgenic Alopecia
ConditionAndrogenetic Alopecia (AGA)
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-65
SponsorJinnah Postgraduate Medical Centre
About this trial
In order to successfully treat androgenetic alopecia (AGA), this study compares the efficacy of low-dose oral minoxidil dosages of 0.25 mg and 1 mg. It addresses a critical gap in current research, as few studies have examined the relationship between low dosage and outcomes like hair diameter, density, patient satisfaction, and adverse effects, including hypertrichosis. Previous research suggests that low dose of oral minoxidil is a safe and well-tolerated option for hair loss, but the optimal dose for maximizing benefits while minimizing side effects remains unclear. This study aims to determine which dose offers the best balance of efficacy and safety for AGA patients.
Eligibility criteria
Qualifiers
Patients have a clinical and trichoscopic diagnosis of mild to severe AGA
Disqualifiers
Patients who, within three months before the trial, had undergone systemic or topical therapies for AGA
People who suffer from additional hair loss conditions such hyperandrogenism, scarring or inflammatory alopecia, or any hormonal disorders.
Sensitivity to minoxidil
Patients with history of severe systemic diseases (heart, renal, or hepatic), a history of hypertension or hypotension, pregnant and breast-feeding women will also be excluded.
Trial design
Treatments tested in this trial
- 2.5% Oral minoxidil
- 1% Oral Minoxidil
Treatment groups
76 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov